Sun Pharma Share Price Target 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030.
Sun Pharma is a multinational pharmaceutical company based in India. It was founded in 1983 by Dilip Shanghvi and is now the world’s fourth-largest specialty generic pharmaceutical company and India’s top pharmaceutical company. Sun Pharma develops and markets a wide range of pharmaceuticals in various therapeutic areas such as psychiatry, neurology, cardiology, gastroenterology, orthopedics, and ophthalmology. The company operates in more than 100 countries and has a strong presence in both developed and emerging markets. Some of Sun Pharma’s well-known products include Abilify, Adalat, Caripill, and Dilantin.
Table of Contents
Business Model of Sun Pharma
Sun Pharma’s business model is focused on developing, manufacturing, and marketing a wide range of pharmaceutical products, including branded formulations, generic drugs, APIs, and OTC products. Here are some key aspects of the company’s business model:
- Product portfolio: Sun Pharma’s product portfolio includes a diverse range of pharmaceutical products in various therapeutic areas. The company develops and markets both branded and generic formulations, which are sold in over 100 countries.
- Research and development: Sun Pharma invests heavily in R&D to develop innovative products and improve its existing product offerings. The company’s R&D efforts are focused on discovering new drugs, improving drug delivery systems, and developing new formulations.
- Manufacturing: Sun Pharma operates manufacturing facilities in several countries, including India, the US, Canada, and Brazil. The company uses advanced manufacturing processes to ensure high-quality products that meet regulatory standards.
- Marketing and distribution: Sun Pharma has a strong marketing and distribution network that allows it to reach healthcare professionals and patients around the world. The company uses a mix of direct sales and partnerships with distributors and wholesalers to market and distribute its products.
- Strategic acquisitions: Sun Pharma has a history of strategic acquisitions to expand its product portfolio and geographic reach. The company has acquired several pharmaceutical companies over the years, including Ranbaxy Laboratories, Pharmalucence, and Pola Pharma.
Shareholding of Sun Pharma
The company’s shareholding is as follows:
- Promoters and promoter group: The promoter and promoter group collectively held 54.75%.
- Foreign institutional investors (FIIs): FIIs held 13.87% of the company’s shares.
- Domestic institutional investors (DIIs): DIIs held 13.35% of the company’s shares.
- Public shareholders: Public shareholders, including retail investors and non-institutional investors, held the remaining 18.03%.
Sun Pharma Share
Sun Pharma’s shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).
As of May 3, 2023, Sun Pharma’s share price on the NSE was INR 962.60/- Sun Pharma Share 52 week high at Rs. 1072.15/- & 52 week low Rs.789.90/-. The P/E Ratio of Sun Pharma Share is 55.10 & Dividend Yield is 0.93%.
| Company Name | Sun Pharmaceutical Industries Limited |
| Share Name | SUNPHARMA |
| Sector | Pharmaceutical |
| Founded in | 1983 |
| Headquarters | Mumbai |
| CEO | Dilip Shanghvi |
| Revenue | ₹39,576 crore (2022) |
| Market Capitalization | ₹ 2,31,000 Cr |
| Primary Exchange | NSE, BSE, |
| Official Website | Click Here |
Sun Pharma Share Price Target 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2040, 2050
| Year | First Target | Second Target |
| 2023 | 1025 | 1090 |
| 2024 | 1140 | 1200 |
| 2025 | 1260 | 1350 |
| 2026 | 1410 | 1490 |
| 2027 | 1530 | 1620 |
| 2028 | 1650 | 1720 |
| 2029 | 1760 | 1830 |
| 2030 | 1910 | 2040 |
| 2040 | 2750 | 2900 |
| 2050 | 3940 | 4200 |
Note:- “That these share price targets for “Sun Pharma Share” are only provided for the purpose of reference and that this prediction will only hold true in the event that there is optimism in the market. Any uncertainties regarding the company or the current state of the global market will not be addressed in this analysis.”
Annual Result Summary of Sun Pharmaceutical Industries Limited
Sun Pharma’s latest annual report covers the fiscal year 2021-2022, Here are some key highlights from the report:
- Consolidated revenue: Sun Pharma’s consolidated revenue for the year was INR 400919 crore , an increase of 16.7% compared to the previous year. The company’s revenue growth was driven by a strong performance in the US and emerging markets.
- Earnings before interest, tax, depreciation, and amortization (EBITDA): Sun Pharma’s consolidated EBITDA for the year was INR 44,813 crore a increase of 60.1% compared to the previous year.
- Net profit: Sun Pharma’s consolidated net profit for the year was INR 34,058 crore , a increase of 49.1% compared to the previous year.
- Debt: As of March 31, 2022, debt down at Rs 4865 million as compared to Rs 5300 million during FY21, a fall of 8.0%.
Sun Pharma Share Price Target 2023
Sun Pharma has a diverse product portfolio that includes branded formulations, generic drugs, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company also has a strong focus on research and development (R&D) and invests a significant portion of its revenue in this area.
Sun Pharma share price target 2023 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2023 | ₹1025 | ₹1090 |
Sun Pharma Share Price Target 2024
Sun Pharma is the world’s fourth-largest specialty generic pharmaceutical company and India’s top pharmaceutical company in terms of market capitalization.The company has a strong focus on research and development (R&D) and invests a significant portion of its revenue in this area. Sun Pharma has 14 R&D centers located around the world.
Sun Pharma share price target 2024 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2024 | ₹1140 | ₹1200 |
Sun Pharma Share Price Target 2025
Sun Pharma has a global workforce of over 30,000 employees and operates manufacturing facilities in India, the United States, Canada, Brazil, Hungary, Israel, and Bangladesh.
Sun Pharma share price target 2025 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2025 | ₹1260 | ₹1350 |
Sun Pharma Share Price Target 2026
Sun Pharma has made several strategic acquisitions to expand its product portfolio and geographic reach. In 2015, the company acquired Ranbaxy Laboratories, which helped it become the largest pharmaceutical company in India. Sun Pharma also acquired Pharmalucence in the US and Pola Pharma in Japan.
Sun Pharma share price target 2026 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2026 | ₹1410 | ₹1490 |
Sun Pharma Share Price Target 2027
Sun Pharma is committed to sustainability and has implemented several initiatives to reduce its environmental footprint, conserve natural resources, and promote social welfare. The company’s sustainability efforts include reducing greenhouse gas emissions, improving energy efficiency, and promoting employee volunteerism and community development programs.
Sun Pharma share price target 2027 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2027 | ₹1530 | ₹1620 |
Sun Pharma Share Price Target 2030
Sun Pharma has received several awards and recognitions for its innovative products and contributions to the pharmaceutical industry. The company was named one of the world’s most innovative companies by Forbes in 2017. Sun Pharma’s shares were listed on the New York Stock Exchange (NYSE) in 2012, making it the first Indian pharmaceutical company to list on the exchange.
Sun Pharma share price target 2030 are as follows –
| Target Year | 1st Target | 2nd Target |
|---|---|---|
| 2030 | ₹1910 | ₹2040 |
joint venture & subsidiaries of sun pharma
Sun Pharma is a pharmaceutical company based in India that operates through various subsidiaries and joint ventures. Some of its notable joint ventures and subsidiaries include:
- Ranbaxy Laboratories Limited: Sun Pharma acquired Ranbaxy in 2015, which was one of the largest pharmaceutical companies in India.
- Taro Pharmaceuticals: Sun Pharma acquired a controlling stake in Taro Pharmaceuticals in 2010, which is a US-based pharmaceutical company.
- Sun Pharmaceutical Industries Inc.: This is Sun Pharma’s subsidiary in the United States, which is responsible for marketing and distributing the company’s products in the US.
- Sun Pharma Advanced Research Company (SPARC): SPARC is a research and development subsidiary of Sun Pharma that focuses on developing innovative drugs and delivery systems.
- Pola Pharma Inc.: Sun Pharma has a joint venture with Pola Pharma, a Japanese pharmaceutical company, to develop and market dermatology products in Japan.
- ACG Worldwide: Sun Pharma has a joint venture with ACG Worldwide, an Indian pharmaceutical packaging company, to develop and manufacture specialty packaging for pharma products.
Dividend History of Sun Pharma Share
the dividend history for the past few years is as follows:
- 2021-22: Sun Pharma declared a dividend of INR 7.5 per share for the fiscal year 2021-22.
- 2020-21: Sun Pharma declared a dividend of INR 5 per share for the fiscal year 2020-21.
- 2019-20: Sun Pharma declared a dividend of INR 3 per share for the fiscal year 2019-20.
- 2018-19: Sun Pharma declared a dividend of INR 2.75 per share for the fiscal year 2018-19.
- 2017-18: Sun Pharma declared a dividend of INR 2.75 per share for the fiscal year 2017-18.
Future of Sun Pharma Share
Some Future details of Sun Pharma –
- Product pipeline: Sun Pharma has a strong focus on R&D and is constantly working on developing new products and improving existing ones. The company’s product pipeline includes a number of promising drugs in various therapeutic areas. The successful development and launch of these drugs could significantly boost Sun Pharma’s revenue and profitability.
- Regulatory environment: The pharmaceutical industry is highly regulated, and changes in regulations could potentially impact Sun Pharma’s operations. For example, changes in drug pricing policies could impact the company’s profitability, while changes in patent laws could affect its ability to launch new products.
- Competition: Sun Pharma operates in a highly competitive industry, and faces competition from other pharmaceutical companies that offer similar products. The company’s ability to differentiate itself and offer innovative products could impact its market share and financial performance.
- COVID-19 pandemic: The ongoing COVID-19 pandemic has had a significant impact on the global economy and the pharmaceutical industry. The pandemic has led to disruptions in supply chains, reduced demand for certain drugs, and increased expenses related to safety measures. Sun Pharma’s ability to navigate these challenges and adapt to the changing environment could be a key factor in its future success.
Risk of Sun Pharma Share
Here are some key risks associated with Sun Pharma:
- Regulatory risks: Sun Pharma operates in a highly regulated industry, and changes in regulations could impact its operations and financial performance. Regulatory risks could include changes in drug pricing policies, patent laws, or other regulations that impact the pharmaceutical industry.
- Competition: Sun Pharma faces competition from other pharmaceutical companies that offer similar products. The company’s ability to differentiate itself and offer innovative products could impact its market share and profitability.
- Intellectual property risks: Sun Pharma’s ability to develop and protect its intellectual property is critical to its success. The company’s patents and other intellectual property rights could be challenged by competitors, potentially impacting its ability to generate revenue from its products.
- Supply chain risks: Sun Pharma sources raw materials and other inputs from suppliers around the world. Disruptions in the supply chain due to factors such as natural disasters, geopolitical tensions, or other events could impact the company’s operations and financial performance.
- Clinical trials risks: Sun Pharma invests heavily in R&D to develop new drugs and improve existing ones. Clinical trials are an important part of this process, but they carry risks such as delays, safety concerns, or failure to meet endpoints, which could impact the company’s ability to bring new drugs to market.
FAQs
Current Target for Sun Pharma Share is Rs.1025/-
Target of Sun Pharma share in 2023 is Rs.1025 to Rs.1090 (approx)
In 2025, Sun Pharma Share will be Rs.1260 to Rs.1350/-
Read Also –
- Maruti Suzuki Share Price Target 2023, 2024, 2025, 2026, 2030
- Asian Paints Share Price Target 2023, 2024, 2025, 2026, 2030
- L&T Share Price Target 2023, 2024, 2025, 2026, 2030
- Titan Share Price Target 2023, 2024, 2025, 2026, 2030
- Mahindra & Mahindra Share Price Target 2023, 2024, 2025, 2026, 2030
- Adani Port (APSEZ) Share Price Target 2023, 2024, 2025, 2026, 2030
